Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company operates in the United States and leverages two main platforms: Cerebrum, a small molecule platform for developing orally available precision therapies, and Solidus, which is used to discover and develop antisense oligonucleotides (ASOs). Its pipeline includes several product candidates in various stages of development, such as ulixacaltamide for essential tremor, relutrigine for SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), vormatrigine for focal epilepsy, and elsunersen for SCN2A-DEE. Additionally, it has preclinical candidates targeting conditions like KCNT1, PCDH19, SYNGAP1, and SCN2A loss-of-function mutations.

Praxis Precision Medicines, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol PRAX. The company's financial reporting and stock trading are conducted in US Dollars (USD). As a US-based company, its shares are traded in the United States, and investors typically use USD to buy and sell its stock. The NasdaqGS is a major US exchange known for listing many biotechnology and technology companies, providing liquidity and visibility for Praxis Precision Medicines among institutional and retail investors.

Praxis Precision Medicines operates in the Healthcare sector and specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing innovative therapies, particularly for central nervous system disorders. The biotechnology industry is characterized by high research and development costs, long development timelines, and significant regulatory oversight. Praxis's work involves advanced platforms like small molecule design and antisense oligonucleotide technology, positioning it within the precision medicine subset of biotech. This sector and industry classification help investors understand the company's risk profile, regulatory environment, and potential for growth based on clinical trial outcomes and drug approvals.

Praxis Precision Medicines, Inc. is headquartered in the United States and primarily serves the US market. The company's description indicates it develops therapies for central nervous system disorders in the United States. While its clinical trials and regulatory filings are likely focused on the US, as a clinical-stage biopharmaceutical company, it may eventually seek approval in other regions. However, based on the available data, its operations and target market are centered in the US. The company collaborates with partners like RogCon Inc. and Ionis Pharmaceuticals, which may support its research and development efforts within the US and potentially beyond.

Praxis Precision Medicines has a diverse pipeline of product candidates targeting various CNS disorders. Key candidates include ulixacaltamide, a small molecule inhibitor of T-type calcium channels in NDA stage for essential tremor; relutrigine, a small molecule in NDA for SCN2A- and SCN8A-DEE and in Phase 3 for broad DEEs; vormatrigine, a sodium-channel modulator in Phase 3 for adjunctive focal epilepsy and Phase 2 for monotherapy focal epilepsy; and elsunersen, a clinical-stage ASO in Phase 3 for SCN2A-DEE. Preclinical candidates include PRAX-020 for KCNT1, PRAX-080 for PCDH19, PRAX-090 for SYNGAP1, and PRAX-100 for SCN2A loss-of-function mutations. These candidates leverage the company's Cerebrum and Solidus platforms, reflecting a focus on precision therapies for genetic and ion channel-related neurological disorders.